黄晨;赵群;吴玉梅;

• 1:首都医科大学附属北京妇产医院妇瘤科

摘要(Abstract)：

目的:研究微RNAs(miRNAs)差异表达与宫颈癌淋巴转移的关系,寻找早期预测淋巴转移的分子标志物及判断患者预后的指标,探讨宫颈癌淋巴转移可能的作用机制。方法:应用安捷伦(Agilent)Human miRNAs V16.0基因芯片检测宫颈癌淋巴转移组与非淋巴转移组的差异表达miRNAs基因,筛选宫颈癌淋巴转移相关miRNAs,并采用实时荧光PCR技术(Real-time PCR)验证芯片结果的准确性,用生物信息学法分析其作用靶点。结果:宫颈癌淋巴转移组中,共筛选出3个显著下调的miRNAs(P<0.05):hsa-miR-31、hsa-miR-31*、hsa-let-7d。其中,hsa-miR-31是宫颈癌淋巴转移组下调最显著的miRNAs。实时荧光PCR验证结果与芯片结果基本吻合。结论:hsa-miR-31抑制肿瘤细胞生长、迁移,在淋巴转移宫颈癌组织中的表达明显下调,它可能成为宫颈癌淋巴转移的分子标志物及治疗靶点。

关键词(KeyWords)： 子宫颈肿瘤;癌,鳞状细胞;基因,肿瘤抑制;微RNAs;miR-31;淋巴转移;基因芯片

Abstract:

Keywords:

基金项目(Foundation): 首都医科大学基础与临床科研合作基金(No:10JL60)

作者(Authors): 黄晨;赵群;吴玉梅;

DOI: 10.13283/j.cnki.xdfckjz.2013.02.013

参考文献(References)：

• [1]Wang X,Wang HK,McCoy JP,et al.Oncogenic HPV in-fection interrupts the expression of tumor-suppressivemiR-34a through viral oncoprotein E6[J].RNA,2009,15(4):637-647
• [2]Fasanaro P,Greco S,Ivan M,et al.microRNA:emergingtherapeutic targets in acute ischemic diseases[J].Phar-macol Ther,2010,125(1):92-104
• [3]Wang V,Wu W.MicroRNA-based therapeutics for cancer[J].BioDrugs,2009,23(1):15-23
• [4]Zimmerman AL,Wu S.MicroRNAs,cancer and cancerstem cells[J].Cancer Lett,2011,300(1):10-19
• [5]Guo C,Pan Q,Li DG,et al.miR-15b and miR-16 are im-plicated in activation of the rat hepatic stellate cell:Anessential role for apoptosis[J].J Hepatol,2009,50(4):776-778
• [6]Martinez I,Gardiner AS,Board KF,et al.Human papi llo-mavirus type 16 reduces the expression of microRNA-218in cervical carcinoma ceils[J].Oncogene,2008,27(18):2575-2582
• [7]Esquela-Kerscher A,Trang P,Wiggins JF,et al.The let-7microRNA reduces tumor growth in mouse models of lungcancer[J].Cell Cycle,2008,7(6):759-764
• [8]Aprelikova O,Yu X,Palla J.The role of miR-31 and itstarget gene SATB2 in cancer-associated fibroblasts[J].Cell Cycle,2010,9(21):4387-4398
• [9]Creighton CJ,Fountain MD,Yu Z.Molecular profiling un-covers a p53-associated role for microRNA-31 in inhibi-ting the proliferation of serous ovarian carcinomas and oth-er cancers[J].Cancer Res,2010,70(5):1906-1915
• [10]Valastyan S,Chang A,Benaich N.Activation of miR-31function in already-established metastases elicits meta-static regression[J].Genes Dev,2011,25(6):646-659
• [11]Augoff K,Das M,Bialkowska K.miR-31 is a broad regu-lator ofβ1-integrin expression and function in cancercells.miR-31 at the mRNA and protein levels multipleαsubunit partners(α2,α5,andαV)ofβ1 integrins andalsoβ3 integrins[J].Mol Cancer Res,2011,9(11):1500-1508
• [12]Adurthi S,Mukherjee G,Krishnamurthy H,et al.Functionaltumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells[J].Int J Gynecol Cancer,2012,22(7):1130-1137
• [13]Hou F,Li Z,Ma D,et al.Distribution of Th17 cells andFoxp3-expressing T cells in tumor-infiltrating lympho-cytes in patients with uterine cervical cancer[J].ClinChim Acta,2012,413(23-24):1848-1854
• [14]Zeng C,Yao Y,Jie W,et al.Up-regulation of Foxp3 par-ticipates in progression of cervical cancer[J].CancerImmunol Immunother,2012[Epub ahead of print]
• [15]Rah B,Amin H,Yousuf K,et al.A novel MMP-2 inhibi-tor 3-azidowithaferin A(3-azidoWA)abrogates cancercell invasion and angiogenesis by modulating extracellu-lar Par-4[J].PLoS One,2012,7(9):e44039
• [16]Pedrioli DM,Karpanen T,Dabouras V,et al.miR-31functions as a negative regulator of lymphatic vascularlineage-specific differentiation in vitro and vascular de-velopment in vivo[J].Mol Cell Biol,2010,30(14):3620-3634
• [17]Dumont N,Tlsty TD.Reflections on miR-ing effects inmetastasis[J].Cancer Cell,2009,16(1):3-4